Search
Selected Filter
Filter Results
Displaying 31–40 of 313 research results
-
May 1, 2023
Eric Pierce Receives Proctor Medal for Outstanding Achievements in Retinal Research
During his Proctor Award Lecture, Dr. Pierce reviewed encouraging clinical trial results for Editas’ CRISPR/Cas9 treatment for people with LCA10
-
Apr 28, 2023
Dr. Tucker is leading the development of GMP facilities for manufacturing clinical grade retinal therapies
-
Apr 21, 2023
Clinical trial participants with advanced vision loss from RP were able to identify fruits and vegetables
-
Apr 19, 2023
Geographic Atrophy: The Advanced Form of Dry AMD
Geographic atrophy causes significant central vision loss and remains an unmet medical need.
-
Mar 30, 2023
Most participants with advanced retinitis pigmentosa (RP) in the trial had improved navigation and/or object discrimination in reduced lighting conditions
-
Feb 18, 2023
Geographic atrophy (GA) is the advanced form of dry age-related macular degeneration (AMD) which causes blindness in one million people in the United States and 5 million worldwide.
This is the first time that a treatment has been approved for this leading cause of blindness.
-
Jan 3, 2023
Opus Genetics Acquires Rights to Gene Therapies for BEST1 and RP (RHO)
The company plans to seek clinical trial authorization for the BEST1 gene therapy during the second half of 2023
-
Dec 2, 2022
SparingVision Receives Authorization to Launch US Clinical Trial for its Cone-Preserving Treatment
The emerging therapy is designed to work independent of the mutated gene causing retinitis pigmentosa
-
Dec 2, 2022
Opus Genetics to Launch Gene Therapy Clinical Trial for LCA5 Patients
The LCA5 gene therapy will be the first emerging Opus treatment to move into a human study
-
Nov 18, 2022
Editas Reports Results for 14 Participants in its Phase 1/2 CRISPR/Cas9 Clinical Trial for LCA10
The company is seeking a partner to move the LCA10 program forward